logo
Plus   Neg
Share
Email

Pharma News Today (TRVN,FPRX,TTPH)

Trevena, Inc. (TRVN) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for OLINVO (oliceridine), a moderate to severe acute pain reliever injection. The Company expects that the PDUFA date for the NDA will be in the fourth quarter of 2018.

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that on December 27, 2017, the company initiated dosing in the Phase 1 portion of the FIGHT Phase 1/3 clinical trial of FPA144, an isoform-selective anti-FGF receptor 2b antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric or gastroesophageal cancer.

Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant infections, announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for intravenous eravacycline for the treatment of complicated intra-abdominal infections.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Payment solutions giant Mastercard has won a patent for a payment system linking Blockchain-based assets to fiat currency accounts. The US patent is a new method to speed up digital currency payments. The document, published by the U.S. Patent and Trademark Office or USPTO, explained that it is a method for managing fractional reserves of blockchain currency. MGM Resorts International Inc. filed federal lawsuits against more than 1,000 victims of last October's deadly mass shooting in Las Vegas in an effort to avoid liability for the incident. MGM owns the Mandalay Bay Resort, from where the gunman Stephen Paddock had launched the attack. Paddock opened fire on a large crowd at an open-air country music concert, killing 58 people. Morgan Stanley (MS) reported 43 percent growth in profit for the second quarter, reflecting strong performance in Investment Banking and sales and trading. Quarterly net revenues rose 12 percent from the prior year. Both earnings per share and revenues topped analysts' expectations.
Follow RTT